

211th Business Plan Presentations Held on October 8, 2019 at Iwasaki Gakuen, Shin-Yokohama, Japan

1. Raisontech Inc. President Mr. Yasushi Sekizawa <http://raisontech.jp/>(Japanese)

Established in July 2017 Capital stock: USD \$ 76,300

Raisontech Inc. is a technology-oriented venture firm engaged in the provision of modules for manufacturers, research and development of advanced technology, and manufacture of original products. Its activities center around technology in the field of electromagnetic induction using sympathetic vibration and resonance. Of particular note are its electromagnetic inductive stylus pen and wireless power supply. The company intends to develop these items into its main pillars while taking up the challenge of a partial IC conversion and changes to improve the ease of use. It is also aiming for the development of business making the most of these items and launching related system services.

【Re-Cap】 For its wireless power supply, Raisontech is targeting the following: 1) household appliance robots, 2) recharging of drones and industrial robots, 3) unlimited mobility and rotation, 4) wireless systems for conference rooms and cafes, 5) premium household appliances that are both intelligent and wireless, 6) optimal charging in harsh environments, and 7) wireless power supply for electric vehicles. Besides tackling these tasks, President Sekizawa said the company is considering the development of battery-less active pens and entry into the field of capsule endoscopy. Its market apparently still has plenty of room for cultivation.



2. System Create Co., Ltd. President Mr. Fumio Watanabe

Established in December 1996 Capital stock: USD \$ 30,000

As part of its activities of solution proposal in response to consultation by companies on various matters, System Create is proposing a "health solution management" platform as a solution for the prevailing issues of health management and a shortage of labor due to population shrinkage and work-style reform. The platform makes full use of the SEV technology (patented technology) developed by WFN K.K.

The platform is expected to heighten corporate value by resolving the "presenteeism" problem in companies, and puts into practice the company's idea that health is a corporate investment.

The proposal of health solution management consists of the following elements: 1) provision of a sense of "healthy satisfaction" to employees, 2) achievement of a pleasant workplace environment, 3) energetic community activities, and 4) creation of value-added business.

The aforementioned platform will provide concrete solutions for keeping people and companies healthy and active.

Application of SEV technology is not confined to the proposal of solutions for health management; it has positive effects on manufacturing equipment etc. It also enables the development of new products incorporating SEV effects as added value, along with reduction of cost. The scope of target businesses includes automobile repair garages, the manufacturing industry, agricultural industry, nursing facilities, medical facilities, and educational institutions. System Create is currently continuing with verification and training activities for them. Some companies have already introduced the technology, which is bringing human benefits and contributing to the development of new products. System Create is convinced that those who get a firsthand experience and grasp of SEV will realize the new possibilities it holds for manufacturing and agriculture. By introducing SEV technology, it is providing a mechanism to energize the proposing companies and increase their earnings.

【Re-Cap】 SEV generates electrons by a combination of natural ore that emits a faint energy and dozens of different types of metal. Applying these electrons to a subject produces an electronic action unique to SEV that can energize the subject. SEV's material energization technology acts on the material itself and thereby reduces energy loss. As a result, it can elicit inherent levels of performance and quality. It may become a proven and highly reliable type of technology for application in health, automobiles, sports gear, home environments, and factory equipment.



3. KINTARO Pharma, Inc. President Mr. Yoji Kishi <https://kintaropharma.com/>(Japanese)

Established in February 2019 Capital stock: USD \$ 20,000

In the future, KINTARO Pharma, Inc. intends to become a manufacturer of cellular medicine in the field of regenerative medicine. It possesses the technical know-how for culturing marrow-derived mesenchymal stem cells, and is going to draw on this know-how in efforts to develop cellular treatment drugs for a plural number of intractable diseases. Its first target disease is Crohn's disease.

The company is hoping to supply a drug that will offer a fundamental treatment for Crohn's disease, an intractable disease of unknown causes. At present, antibodies and other types of drugs are administered for it, but there is no possibility of a definitive treatment. KINTARO Pharma's subsidiaries have already accumulated a wealth of diverse clinical experience outside Japan, and its drug discovery projects are at very little risk of impasse in the process of clinical trials. For its regenerative medicine and other products, it is working to gain initial authorization in five years, seeing that understanding of the same is growing at Japan's Pharmaceutical and Medical Devices Agency (PMDA), and that the "sakigake" (pioneer) scheme for early approval is now in place. The term "regenerative medicine" refers to treatment aimed at the regeneration of a bodily part or recovery of a bodily function lost due to injuries caused by accidents etc. or to disease. In short, the purpose is to regenerate organs or tissue in the body and restore their functions to the original state. While such medicine was the stuff of dreams until only recently, some types are already coming into general practice, as evidenced by the case of skin transplants. Particular interest is coming to focus on stem cell treatment drugs. The company is pursuing research on KINTARO Cell, a marrow-derived stem cell, together with Tokyo Medical University. It is analyzing differences between cells from young donors and those from elderly donors, and plans to publish the research data in a medical journal. It expects various mesenchymal stem cells not only to discharge the role of lengthening the healthy life spans of a wider circle of people but also to make a vital contribution to society, in areas including the future advancement of regenerative medicine and drug discovery.

【Re-Cap】 KINTARO Pharma has developed stem cells that are closer to natural ones by applying Japanese culturing technology to the foundation of 50 years of research dating from the Soviet era. President Kishi said that his company's group has eight years of clinical experience overseas. He also asserted that the KINTARO Cell is characterized by a low level of risk at the stage of clinical trials and a high return. Going forward, the market for regenerative medicine could possibly expand greatly. KINTARO Pharma wants to increase the number of pipelines every two years and lead the market, President Kishi added.



《Impressions》 At this meeting, I was struck by the way the representatives of the companies making presentations searched for areas in which they could collaborate with each other. If your company would like to make a presentation at the meeting, please contact us at an early date, because the schedule is filled up for a few months in advance.

**NPO Venture Support Mechanism
MINERVA
TNP Partners / TNP On The Road
TNP THREADS OF LIGHT**